Failure of Deferasirox, an Iron Chelator Agent, Combined with Antifungals in a Case of Severe Zygomycosis
暂无分享,去创建一个
J. Mira | A. Cariou | O. Lortholary | O. Scatton | E. Dannaoui | A. Paugam | A. Soummer | V. Lemiale | A. Mathonnet | P. Massault
[1] B. Spellberg,et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. , 2007, The Journal of clinical investigation.
[2] B. Spellberg,et al. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. , 2006, The Journal of antimicrobial chemotherapy.
[3] B. Spellberg,et al. Deferasirox, an Iron-Chelating Agent, as Salvage Therapy for Rhinocerebral Mucormycosis , 2006, Antimicrobial Agents and Chemotherapy.
[4] Brad Spellberg,et al. Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management , 2005, Clinical Microbiology Reviews.
[5] B. Spellberg,et al. Combination Therapy with Amphotericin B Lipid Complex and Caspofungin Acetate of Disseminated Zygomycosis in Diabetic Ketoacidotic Mice , 2005, Antimicrobial Agents and Chemotherapy.
[6] B. Spellberg,et al. Rhizopus oryzae Adheres to, Is Phagocytosed by, and Damages Endothelial Cells In Vitro , 2005, Infection and Immunity.
[7] O. Lortholary,et al. Vascularites secondaires aux infections fongiques , 2004 .
[8] F. Marty,et al. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. , 2004, The New England journal of medicine.
[9] O. Lortholary,et al. [Vasculitis secondary to fungal infections]. , 2004, Presse medicale.
[10] J. Meis,et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. , 2003, The Journal of antimicrobial chemotherapy.
[11] Y. Schneider,et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. , 1993, The Journal of clinical investigation.